|
|
|
25.11.25 - 20:12
|
Grid-Scale Battery Boom Sparks Lithium′s Comeback (ZeroHedge)
|
|
|
Grid-Scale Battery Boom Sparks Lithium's Comeback
Lithium prices have awakened from a multi-year bust in the second half of this year, with Chinese lithium carbonate prices jumping from $6,000 a ton to $11,000 a ton, driven by what Goldman analysts describe as "temporary Chinese supply cuts" and "strong energy-storage-system (ESS) demand."
For some context, lithium markets flipped dramatically from the 2020 to 2022 "white-gold supercycle" hype to a two-year bust cycle as supply collided with much softer-than-expected worldwide EV demand growth.
With the EV adoption curve stalled and consumers balked at record-high new-car prices amid high interest rates, lithium prices have been on the rise due to a major surprise: tightening near-term supply and rising ESS demand.
"This leads us to delay the timing of a price correction we still expect to the latter half of 2026. We maintain our view that supply delays will be required by 2027 to rebalance the market,&quo...
|
|
|
|
|
25.11.25 - 14:33
|
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 at the Georgia World Congress Center in Atlanta, Georgia. Seven posters will be presented, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), and data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice. Xenon's poster presentations also include findings on the impact of depression on epilepsy patients, as well as new pre-clinical data from the Company's early-stage NaV1.1 program in Dravet syndrome....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.11.25 - 22:24
|
My No. 1 Stock for Canadian Investors in 2026 and Beyond (Fool)
|
|
|
Fortis (TSX:FTS) is, hands-down, the best opportunity in the market right now for long-term investors, in my humble opinion.
The post My No. 1 Stock for Canadian Investors in 2026 and Beyond appeared first on The Motley Fool Canada....
|
|
|
|
|
|
|
18.11.25 - 19:30
|
These 3 Dividend Stocks Are Perfect for Any Portfolio (24/7 Wall St.)
|
|
|
Certain dividend stocks are worth holding no matter what your portfolio looks like. Dividend stocks like Fortis (NYSE:FTS), Verizon (NYSE:VZ), and Atmos Energy (NYSE:ATO), have stood the test of time and do well as long-term strategic plays. Plus, they can act as stabilizers for your entire portfolio if the market starts getting more volatile. The ... These 3 Dividend Stocks Are Perfect for Any Portfolio
The post These 3 Dividend Stocks Are Perfect for Any Portfolio appeared first on 24/7 Wall St.....
|
|
|
|
|
18.11.25 - 03:36
|
1 No-Brainer Buy and Hold Canadian Stock (Fool)
|
|
|
Atco combines regulated utilities, essential infrastructure, and conservative management into a low-drama, buy-and-hold stock built for steady compounding.
The post 1 No-Brainer Buy and Hold Canadian Stock appeared first on The Motley Fool Canada....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
